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Abstract: In this study, we aimed to explore whether a common single nucleotide polymorphism 
(SNP), rs266729 (-11,377C . G), in the adiponectin C1Q and collagen domain containing 
(ADIPOQ) gene could influence weight reduction and fat change under sibutramine therapy 
in an obese population. There were 131 obese Taiwanese patients, including 44 in the placebo 
group and 87 in the sibutramine (10 mg daily) group. We assessed the measures of weight loss 
and body fat reduction at the end of the 12-week treatment period by analysis of covariance 
(ANCOVA) models using gender, baseline weight, and baseline percent body fat as covari-
ates. By comparing the placebo and sibutramine groups with ANCOVA, our data revealed a 
strong effect of sibutramine on percent body fat loss (1.9 ± 0.3 vs 4.6 ± 0.5%; P , 0.001) and 
on weight reduction (2.8 ± 2.0 vs 7.9 ± 1.6 kg; P , 0.001) for subjects with the CC genotype. 
On the contrary, sibutramine had no significant effect on percent body fat loss or on weight 
loss in the GG and GC individuals. The results suggest that the SNP rs266729 of the ADIPOQ 
gene may contribute to weight reduction and fat loss in response to sibutramine therapy in 
Taiwanese obese patients.
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Introduction
Sibutramine is one of the two agents currently approved for the long-term manage-
ment of obesity in Taiwan and was recently withdrawn from the European   market 
(through the European Medicines Agency) due to safety issues. Sibutramine 
reduces food intake and induces weight loss by selectively inhibiting the neuronal 
reuptake of serotonin and norepinephrine within the hypothalamus.1,2 Several 
studies3–7 in pharmacogenetics have revealed that some genetic variants, such as 
the C-1291G (rs1800544) single nucleotide polymorphism (SNP) in the adrener-
gic alpha-2A-receptor (ADRA2A) gene, the C825T (rs5443) SNP in the guanine 
nucleotide binding protein beta polypeptide 3 (GNB3) gene, the serotonin trans-
porter gene-linked polymorphic region (5-HTTLPR) variant in the solute carrier 
family 6 member 4 (SLC6A4; serotonin neurotransmitter transporter) gene, and the 
G-866A (rs659366) SNP in the uncoupling protein 2 (UCP2) gene, were associated 
with weight reduction and body composition with sibutramine treatment in obese 
patients in different populations.
Adiponectin is an adipose-derived plasma protein, which is known to modulate 
insulin sensitivity and glucose homeostasis, and has been well known to be linked 
with metabolic syndrome.8 It has been shown that serum adiponectin levels were 
increased during sibutramine treatment in obese nondiabetic subjects.9,10 Furthermore, Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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it has been reported that serum adiponectin was elevated in 
rats which received sibutramine with high fat diet in a recent 
animal study.11 Adiponectin is encoded by the adiponectin 
C1Q and collagen domain containing (ADIPOQ) gene, which 
locates on chromosome 3q27.12 A common SNP, rs266729 
(-11,377C . G), in the proximal promoter region of the 
ADIPOQ gene has drawn much attention. The ADIPOQ 
rs266729 variant has been identified to be associated with 
obesity, body mass index (BMI), type 2 diabetes, diabetic 
nephropathy, and insulin sensitivity.13–19 Moreover, evi-
dence indicates that the ADIPOQ rs266729 polymorphism 
functionally regulates adiponectin promoter activity and its 
protein levels in blood.20,21 In addition, ADIPOQ rs266729 
has been found to be correlated with circulating adiponectin 
levels in diabetes and obesity.13,22–24
Our previous findings6,7 mainly reported of the   association 
studies of sibutramine with the GNB3 rs5443 and UCP2 
rs659366 polymorphisms. In this work, we extended the 
previous research to test the hypothesis that ADIPOQ 
rs266729 may influence weight loss and fat change in 
response to sibutramine treatment amongst Taiwanese obese 
individuals.
Patients and methods
Patients
Our patient cohort was original to the previous study by 
Hsiao and colleagues6 and was described in detail elsewhere.6 
Briefly, obese Taiwanese patients were recruited from the 
Taipei Medical University Hospital in Taipei, Taiwan in 
2008. All the recruited patients fulfilled the following inclu-
sion criteria: (1) aged between 18 and 65 years old; (2) a 
BMI $ 25 kg/m2. We used Asian-adapted definitions25,26 
of obesity based on BMI: nonobese (BMI , 25 kg/m2) and 
obese (BMI $ 25 kg/m2). Subjects with cardiovascular 
diseases or with concomitant medications were excluded 
from the study. The intent-to-treat population consisted of 
131 individuals in a randomized clinical trial, including 87 
in the sibutramine (10 mg daily) group and 44 in the placebo 
group. Five subjects in the sibutramine group and seven 
in the placebo group dropped out before the study period 
was completed. Before conducting the study, approval was 
obtained from the Internal Review Board of the Taipei Medi-
cal University Hospital. The approved informed consent form 
was signed by each subject.
The first endpoint was percent body fat loss after 12 weeks 
versus baseline.6 The second endpoint was weight loss at the 
end of 12 weeks compared to baseline. Total body fat was 
measured by dual energy x-ray absorptiometry (Lunar Corp, 
Madison, WI, USA).
Laboratory methods
DNA was isolated from blood samples using QIAamp® DNA 
blood kit following the manufacturer’s instructions (Qiagen, 
Valencia, CA, USA). To extract DNA, we used 200 µL of 
blood which was further solved in 200 µl of distilled water.19 
Before polymerase chain reaction (PCR), part of the extracted 
DNA was diluted into a concentration of 10 µg/µL. The 
qualities of isolated genomic DNAs were checked using the 
agarose gel electrophoresis and the quantities determined 
using spectrophotometry.
All SNP genotypings were performed using the Taqman 
SNP genotyping assay (Applied Biosystems [ABI], Foster 
City, CA, USA).6 The primers and probes of SNPs were from 
the ABI Assays-on-Demand™ kit. Reactions were carried 
out according to the manufacturer’s protocol. The probe 
fluorescence signal detection was performed using the ABI 
Prism 7900® Real-Time PCR System.
statistical analysis
We assessed the categorical data at baseline using the χ2 test 
and compared differences for continuous variables at baseline 
using analysis of variance (ANOVA). Genotype frequencies 
were evaluated for Hardy-Weinberg equilibrium using a χ2 
goodness-of-fit test. The measures of weight loss and body 
fat reduction at the end of the treatment period were analyzed 
by analysis of covariance (ANCOVA) models using gender, 
baseline weight, and baseline percent body fat as covariates.6 
For each endpoint (percent body fat loss or weight loss), 
three separate ANCOVA models were used and stratified for 
the CC, GG, and GC groups, respectively. The criterion for 
significance was set at P , 0.05 for all tests.
Results
Tables 1 and 2 present the demographic characteristics of the 
study population for the sibutramine group and the placebo 
group, respectively. In the sibutramine group, the GG, GC, 
and CC genotypes had similar distribution of sex, baseline 
weight, and baseline percent body fat (Table 1; P = 0.478, 
0.586, and 0.575, respectively). Similarly, the distribution 
of sex, baseline weight, and baseline percent body fat in the 
GG, GC, and CC genotypes was well matched in the placebo 
group (Table 2; P = 0.093, 0.299, and 0.42, respectively). 
ADIPOQ rs266729 genotype frequency distributions were 
in Hardy-Weinberg equilibrium (P = 0.21).Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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First, we analyzed influence of ADIPOQ genotype 
on effect of 12-week sibutramine treatment on body fat 
composition by ANCOVA models, adjusting for gender, 
baseline weight, and baseline percent body fat as covariates. 
By comparing the sibutramine and placebo groups, a strong 
effect of sibutramine on percent body fat loss was indicated 
for subjects with the CC genotype (Table 3; 4.6 ± 0.5 vs 
1.9 ± 0.3%; P , 0.001). On the contrary, sibutramine had 
no significant effect on percent body fat loss in subjects with 
the GG and GC genotypes (Table 3; P = 0.383 and 0.814, 
respectively). We further considered putting GG and GC 
individuals together in the analysis, and sibutramine showed 
no significant effect on percent body fat loss in this combined 
GG and GC group (P = 0.638).
Additionally, there was no significant difference on per-
cent body fat loss among the GG, GC, and CC individuals 
in either the sibutramine group (P = 0.061) or the placebo 
group (P = 0.725).
Furthermore, we investigated influence of ADIPOQ 
genotype on effect of sibutramine treatment on weight loss 
using ANCOVA after covariate adjustment with gender, 
baseline weight, and baseline percent body fat. By compar-
ing the sibutramine and placebo groups, a strong effect of 
sibutramine on weight reduction was observed in individuals 
with the CC genotype (Table 4; 7.9 ± 1.6 vs 2.8 ± 2.0 kg; 
P , 0.001). In contrast, sibutramine caused no significant 
effect on weight loss in subjects with the GG and GC 
genotypes (Table 4; P = 0.417 and 0.055, respectively). 
Furthermore, we considered combining GG and GC sub-
jects together in the analysis, and sibutramine showed no 
significant effect on weight loss in this combined GG and 
GC group (P = 0.054).
In addition, a genotype-dependent difference was not 
observed in weight loss amongst the GG, GC, and CC indi-
viduals within either the sibutramine (P = 0.205) or placebo 
(P = 0.277) groups.
Discussion
Our study is the first to date to have examined whether 
ADIPOQ rs266729 is significantly associated with weight 
reduction and body composition under sibutramine therapy 
amongst Taiwanese obese individuals. Our analyses showed 
that treatment with sibutramine resulted in significantly 
greater reduction of body fat and weight for specific ADIPOQ 
rs266729 CC genotype as compared to the placebo group 
with the same genotype. As mentioned in the   Introduction, 
Table 1 Demographic characteristics of study subjects for the sibutramine group
GG GC CC P valuea
number 7 (9%) 28 (34%) 47 (57%)
Age, years 27.7 ± 2.9 32.5 ± 5.1 31.7 ± 4.8 0.582
gender, % male 28.6 50.0 53.2 0.478
Height, cm 165.2 ± 8.3 166.6 ± 9.6 167.2 ± 7.7 0.568
Weight at baseline, kg 82.4 ± 22.9 79.8 ± 11.4 82.8 ± 13.4 0.586
BMi at baseline, kg/m2 29.9 ± 6.8 28.7 ± 3.0 29.5 ± 3.3 0.964
Percent body fat at baseline, % 35.1 ± 8.6 32.5 ± 7.0 32.7 ± 6.4 0.575
Data are presented as mean ± standard deviation.
aP values refer to AnOVA analyses for continuous variables and the χ2 test for the categorical data.
Abbreviation: BMi, body mass index.
Table 2 Demographic characteristics of study subjects for the placebo group
GG GC CC P valuea
number 4 (11%) 13 (35%) 20 (54%)
Age, years 34.8 ± 9.8 31.5 ± 6.2 30.1 ± 4.5 0.145
gender, % male 25.0 76.9 45.0 0.093
Height, cm 162.0 ± 7.4 168.2 ± 8.1 166.6 ± 9.4 0.631
Weight at baseline, kg 76.6 ± 10.8 82.4 ± 15.1 85.2 ± 15.8 0.299
BMi at baseline, kg/m2 29.1 ± 1.6 28.9 ± 3.1 30.5 ± 3.8 0.128
Percent body fat at baseline,% 36.3 ± 4.0 31.8 ± 3.9 35.6 ± 5.7 0.420
Data are presented as mean ± standard deviation.
aP values refer to AnOVA analyses for continuous variables and the χ2 test for the categorical data.
Abbreviation: BMi, body mass index.Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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weight reduction with sibutramine treatment in obese 
  subjects has previously been shown to be associated with 
some variations in other candidate genes, including the 
rs1800544 (C-1291G) SNP in the ADRA2A gene,5 the 
rs5443 (C825T) SNP in the GNB3 gene,3,5,6 the 5-HTTLPR 
variant in the SLC6A4 gene,4,5 and the rs659366 (G-866A) 
SNP in the UCP2 gene.7 Thus, a promising finding reported 
for the first time was that ADIPOQ rs266729 may play a key 
role in modulating treatment outcomes with sibutramine in 
Taiwanese obese subjects.
One may concern the potential biological mechanism 
under the strong dependency of the sibutramine effect 
between the ADIPOQ genotype and body fat. ADIPOQ 
encodes adiponectin expressed exclusively in both white 
and brown adipose tissues.27 Recent evidence has indicated 
that the G allele of ADIPOQ rs266729 alters the sequence 
for one of transcriptional stimulatory protein binding sites 
and subsequently reduces adiponectin promoter activity.20,28 
Furthermore, several studies have demonstrated that there 
was an association between adiponectin and adipose tis-
sue mass in adults, and suggested that adiponectin secre-
tion and circulating levels were inversely proportional to 
body fat.29–31 It has been shown that adiponectin expression 
from adipose tissue was lower in obese subjects, and there 
was an overall significant decrease in plasma adiponectin 
with increasing body fat.30 Moreover, it has been reported 
that body weight reduction increased the plasma levels of 
  adiponectin in obese patients who received gastric partition 
surgery, implicating that the expression of adiponectin may 
be under a strict   feedback regulation in   obesity and body fat 
mass.29 In addition, an animal study revealed that adiponectin 
was decreased in obesity and was completely absent in mice 
without adipose tissues.32 In that animal study, adiponectin 
was also indicated to prevent the accumulation of lipids in 
insulin target tissues by stimulating oxidation of fatty acids 
primarily in muscle and liver.32
Another concern involves whether the results reported 
here were influenced by a nonrandomized patient selection 
for genotyping. However, it seems unlikely that this is the 
case because allele frequencies for ADIPOQ rs266729 were 
in accordance with HapMap database entries33 and with previ-
ous studies.13–24 Furthermore, we did not observe significant 
deviations from Hardy-Weinberg equilibrium (P = 0.21). Our 
findings should be confirmed by regenotyping in nonobese 
controls to detect genotype-specific differences.
There were several limitations to this study as follows. 
First, the contributions of other markers in ADIPOQ should 
be further examined in future work. As discussed previously, 
the selected SNP rs266729 has been suggested by previ-
ous studies as positive associations with metabolism.13–24 
We assumed that an SNP, which has been investigated in 
several studies, might be a good candidate to explore the 
genetic role of the ADIPOQ gene tested in the current pilot 
study.19 There were some SNPs in ADIPOQ shown to be 
associated with metabolism. However, ADIPOQ rs266729 
was one of the most mentioned SNPs in previous reports.13–24 
Second, our results could be different after a longer time of 
intervention with sibutramine.34 Third, by chance findings 
could not be excluded because a small group was investi-
gated, and large prospective clinical trials are necessary in 
future work. In addition, the side effects of sibutramine and 
a follow up study after 12 weeks should be further investi-
gated. Future research is also needed to check if ADIPOQ 
rs266729 changes any binding sites in the promoter region 
of the human adiponectin. Moreover, these findings may not 
be generalizable to other populations. Ethnically-matched 
studies would be necessary to know if such association is 
found in non-Taiwanese subjects.
Conclusion
In conclusion, our findings support the hypothesis that 
  ADIPOQ rs266729 may help predict weight reduction and 
fat loss in response to sibutramine therapy together with 
other markers found in some previous studies.3–7 Independent 
Table 4 Weight loss after sibutramine treatment by ADiPOQ 
genotype
Sibutramine Placebo P valuea
CC 7.9 ± 1.6 kg 2.8 ± 2.0 kg ,0.001
gg 6.7 ± 1.6 kg 4.4 ± 0.6 kg 0.417
gC 6.7 ± 1.0 kg 4.8 ± 0.7 kg 0.055
Data are presented as mean ± standard deviation (adjusted for covariates from 
AnCOVA analyses).
aP values are based on AnCOVA models.
Abbreviation: ADiPOQ, adiponectin C1Q and collagen domain containing.
Table 3 Percent body fat loss after sibutramine treatment by 
ADiPOQ genotype
Sibutramine Placebo P valuea
CC 4.6% ± 0.5% 1.9% ± 0.3% ,0.001
gg 3.5% ± 0.6% 1.8% ± 0.4% 0.383
gC 3.2% ± 0.4% 3.0% ± 0.3% 0.814
Data are presented as mean ± standard deviation (adjusted for covariates from 
AnCOVA analyses).
aP values are based on AnCOVA models.
Abbreviation: ADiPOQ, adiponectin C1Q and collagen domain containing.Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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replications are needed to confirm the role of the ADIPOQ 
rs266729 polymorphism found in this study.
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